Safety and efficacy of exenatide as monotherapy and adjunctive therapy to oral antidiabetic agents in adolescents with type 2 diabetes
Phase of Trial: Phase III
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors AstraZeneca
- 10 Jun 2017 Biomarkers information updated
- 23 May 2016 Planned primary completion date changed from 1 May 2017 to 1 Aug 2018.
- 14 Oct 2014 Planned End Date changed from 1 Dec 2014 to 1 May 2020 as reported by ClinicalTrials.gov record.